Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-17 12:30 • The Motley Fool Positive Axe Cap view: Selective

Rising AI adoption is driving massive energy demand from data centers, positioning nuclear energy—particularly small modular reactors (SMRs)—as an ideal solution. NuScale Power and Oklo are two early-stage SMR companies positioned to benefit from this trend, though both face regulatory hurdles and commercialization risks. Major investment banks including Goldman Sachs, Bank of America, and Morgan Stanley are bullish on nuclear's renaissance.

Axe note: Rising AI-driven power demand shines a spotlight on nuclear energy solutions, but South African investors must tread carefully.

2026-07-17 12:30 • The Motley Fool Positive Axe Cap view: Selective

Revolution Medicines, a pre-revenue biotech company developing targeted cancer treatments to replace chemotherapy, has surged 125% in 2026. The company's flagship drug Daraxonrasib received FDA Breakthrough Therapy designation and is undergoing accelerated review by the EMA. Billionaire Stanley Druckenmiller's Duquesne Family Office purchased 316,000 shares worth $30.6 million in Q1 2026, now valued at $56.6 million, signaling confidence in the company's potential despite its speculative nature.

Axe note: RVMD has soared 125% in 2026 on breakthrough cancer treatment hopes, but South African investors should tread carefully.

2026-07-17 12:19 • The Motley Fool Neutral Axe Cap view: Neutral

Tesla's Q2 earnings on July 22 are expected to show strong EV delivery growth (~480k units) and automotive revenue around $20.1-20.7B, up 22% YoY. However, the article suggests investors shouldn't rush to buy before earnings as major announcements on Optimus robots or robotaxi/v15 software are unlikely, with no game-changing catalysts expected. Long-term investors can wait to buy as the stock lacks near-term catalysts.

Axe note: Tesla's July 22 earnings promise growth but no local catalyst to jump in now.